Concord Biotech Ltd Sees Mixed Technical Signals Amid Price Momentum Shift

Price Movement and Market Context

On 29 Sep 2026, Concord Biotech’s share price closed at ₹1,394.15, down 4.13% from the previous close of ₹1,454.20. The intraday range saw a high of ₹1,451.05 and a low of ₹1,387.00, indicating some volatility within the session. The stock remains below its 52-week high of ₹1,667.00 but comfortably above its 52-week low of ₹987.05, suggesting a recovery phase after a period of weakness.

Comparatively, the stock’s recent returns have underperformed the broader Sensex index in the short term. Over the past week, Concord Biotech declined by 11.8%, significantly steeper than the Sensex’s 2.79% fall. Over one month, the stock’s loss of 5.94% slightly exceeded the Sensex’s 5.81% decline. However, year-to-date (YTD), Concord Biotech has delivered a positive return of 3.62%, outperforming the Sensex’s negative 14.61% return, highlighting resilience amid broader market challenges.

Technical Indicator Analysis

The technical landscape for Concord Biotech is nuanced. The Moving Average Convergence Divergence (MACD) indicator shows a bullish signal on the weekly chart, suggesting upward momentum in the near term. Conversely, the monthly MACD is mildly bearish, indicating potential medium-term pressure. This divergence between weekly and monthly MACD readings points to a possible consolidation phase or a pause in the uptrend.

The Relative Strength Index (RSI) on both weekly and monthly timeframes currently shows no definitive signal, implying that the stock is neither overbought nor oversold. This neutral RSI reading suggests that the stock’s price momentum is balanced, awaiting a catalyst to drive a decisive move.

Bollinger Bands provide further insight: the weekly bands are mildly bullish, indicating that price is trending towards the upper band, a sign of strength. However, the monthly Bollinger Bands are bearish, reflecting wider price volatility and potential downward pressure over the longer term.

Moving Averages and Trend Assessment

Daily moving averages for Concord Biotech are mildly bullish, with short-term averages likely positioned above longer-term averages, signalling a tentative upward trend. However, the weekly KST (Know Sure Thing) indicator is bearish, and the Dow Theory assessment on the weekly chart is mildly bearish as well, suggesting caution for medium-term investors. On the monthly scale, Dow Theory indicates no clear trend, reinforcing the mixed technical signals.

On-Balance Volume (OBV) readings show no clear trend on either weekly or monthly charts, indicating that volume is not currently confirming price movements. This lack of volume confirmation can be a warning sign that the current price action may lack conviction.

Mojo Score and Rating Upgrade

Concord Biotech’s MarketsMOJO score currently stands at 50.0, reflecting a Hold rating. This represents an upgrade from the previous Sell rating as of 31 Jul 2026, signalling improved technical and fundamental outlooks. The company is classified as a small-cap within the Pharmaceuticals & Biotechnology sector, which often entails higher volatility but also growth potential.

The upgrade to Hold suggests that while the stock is not yet a strong buy, it has stabilised sufficiently to warrant investor attention, particularly given its outperformance relative to the Sensex on a year-to-date basis and its positive three-year return of 34.3%, which significantly exceeds the Sensex’s 11.09% over the same period.

Long-Term Performance and Sector Context

Over the longer term, Concord Biotech’s performance has been robust. Although five- and ten-year returns are not available for the stock, the three-year return of 34.3% is a strong indicator of sustained growth. This compares favourably with the Sensex’s 11.09% gain over the same timeframe, underscoring the company’s ability to outperform the broader market despite recent short-term volatility.

Within the Pharmaceuticals & Biotechnology sector, Concord Biotech faces competitive pressures but benefits from ongoing demand for biotechnological innovations and pharmaceutical products. The sector’s inherent cyclicality and regulatory environment require investors to carefully monitor technical signals alongside fundamental developments.

Investor Takeaway and Outlook

Investors in Concord Biotech should approach the stock with a balanced perspective. The mildly bullish daily moving averages and weekly MACD suggest potential for near-term gains, but the bearish signals from monthly MACD, Bollinger Bands, and KST indicators counsel caution. The absence of strong volume confirmation further emphasises the need for prudence.

Given the stock’s recent price decline of over 4% on the day and a sharper weekly drop of 11.8%, short-term traders may find opportunities in volatility, while long-term investors should monitor for confirmation of trend reversals before increasing exposure.

Overall, Concord Biotech’s technical parameters indicate a stock in transition, with momentum shifting but not yet decisively trending. The Hold rating and Mojo Score of 50.0 reflect this intermediate stance, suggesting that investors maintain positions but await clearer signals before committing additional capital.

Summary of Key Technical Metrics:

• Current Price: ₹1,394.15 (down 4.13% on 29 Sep 2026)
• 52-Week Range: ₹987.05 – ₹1,667.00
• MACD: Weekly Bullish, Monthly Mildly Bearish
• RSI: Neutral on Weekly and Monthly
• Bollinger Bands: Weekly Mildly Bullish, Monthly Bearish
• Moving Averages: Daily Mildly Bullish
• KST: Weekly Bearish
• Dow Theory: Weekly Mildly Bearish, Monthly No Trend
• OBV: No clear trend
• Mojo Score: 50.0 (Hold, upgraded from Sell on 31 Jul 2026)

Investors should continue to monitor these indicators closely, particularly the monthly MACD and Bollinger Bands, for signs of either a sustained recovery or further correction in Concord Biotech’s share price.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →